Ethical Considerations Raised by Clinical Trials

  • Richard Foa

Abstract

Many of the ethical issues raised by clinical trials in multiple sclerosis (MS) are no different from those that arise in clinical research in other diseases. They are the basic ethical problems of the conduct of research on human subjects, more specifically, the problems of research on ill and vulnerable human subjects.

Keywords

Placebo Toxicity Dementia Marketing Explosive 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Annas GJ, Grodin MA (1992) The Nazi doctors and the Nuremberg Code. Oxford University Press, New York, pp 102–103,331–342 xGoogle Scholar
  2. Beecher HK (1966) Ethics and clinical research. N Engl J Med 274: 1354–1360PubMedCrossRefGoogle Scholar
  3. Clinical Research Subcommittee of the Scientific Issues Committee, American Academy of Neurology (1995) Status of clinical research in neurology. Neurology 45: 839–845Google Scholar
  4. Confavreaux C, Paty D (1995) Current status of computerization of multiple sclerosis clinical data for research in Europe and North America: the EDMUS/MS-COSTAR connection. Neurology 45: 573–576Google Scholar
  5. Curran WJ (1973) The Tuskegee syphilis study. N Engl J Med 289: 730–731PubMedCrossRefGoogle Scholar
  6. Emanuel E, Steiner D (1995) Institutional conflicts of interest. N Engl J Med 332: 262–267PubMedCrossRefGoogle Scholar
  7. Fischl MA, Richman DD, Grieco MH et al. (1987) The efficacy of azidothymidine ( AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317: 185–191PubMedCrossRefGoogle Scholar
  8. Freedman B (1987) Equipoise and the ethics of clinical research. N Engl J Med 317: 141–145PubMedCrossRefGoogle Scholar
  9. Goodkin D, Kanoti G (1994) Ethical considerations raised by the approval of interferon beta-lb for the treatment of multiple sclerosis. Neurology 44: 166–170PubMedGoogle Scholar
  10. IFNB Multiple Sderosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661Google Scholar
  11. Kampmeier RH (1972) The Tuskegee study of untreated syphilis. South Med J 65:1247–1251 Kampmeier RH (1974) Final report on the “Tuskegee Syphilis Study”. South Med J 67:1349–1353 Katz J (1993) “Ethics and clinical research” revisited: a tribute to Henry K. Beecher. Hastings Cent Rep 23 (5): 31–39Google Scholar
  12. Munson R.(ed) (1992) Intervention and reflection: basic issues in medical ethics, 4th edn. Wadsworth, Belmont, CA, pp 392–394Google Scholar
  13. Noseworthy J, Ebers G, Vandervoort M, Farquhar R, Yetisir E, Roberts R (1994) The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 44: 16–20PubMedGoogle Scholar
  14. Rothman DJ (1987) Ethics and human experimentation. N Engl J Med 317: 1195–1199PubMedCrossRefGoogle Scholar
  15. Rothman KJ, Michels KB (1994) The continuing unethical use of placebo controls. N Engl J Med 331: 394–398PubMedCrossRefGoogle Scholar
  16. Spilker B (1991) Guide to clinical trials. Raven Press, New York, pp 124–128Google Scholar
  17. Volberding PA, Lagakos SW, Koch MA et al. (1990) Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 322: 941–949PubMedCrossRefGoogle Scholar
  18. Whitaker JN, McFarland HF, Rudge P, Reingold, SC (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1: 37–47PubMedGoogle Scholar
  19. Wittes, J (1994) Monitoring clinical trials: relationships among data monitoring board, sponsor, and investigators [Abstract]. In: Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. A Meeting of the National Multiple Sclerosis Society; 1994 Feb; Charleston, SCGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1996

Authors and Affiliations

  • Richard Foa

There are no affiliations available

Personalised recommendations